Treatment of Cervical Cancer at Primary FIGO Stage IVB or Recurrent/Persistent Disease with Performance Status Below 2
Clinical Scenario
This protocol addresses patients with cervical cancer presenting at primary FIGO stage IVB — distant metastatic disease — or with recurrent or persistent disease following prior treatment, where the patient's performance status remains below 2 (ECOG 0 or 1).
Patient Selection & Eligibility
Palliative-intent chemotherapy aimed at symptom relief and quality-of-life preservation is indicated when the patient has a performance status below 2 and no formal contraindications. Patients with primary stage IVB or recurrent/persistent disease and measurable disease are candidates for systemic treatment evaluation according to evidence-based combination regimens.
Treatment Approach (Partial Overview)
The regimen in this setting involves second-line cytostatic chemotherapy. Specific cytostatic agents have been evaluated in patients progressing following first-line therapy — the complete selection, sequencing, and criteria are detailed in the full protocol.
Full regimen details, agent selection criteria, and clinical decision algorithm available in the structured protocol.
References
- Palliative chemotherapy with the aim of relieving symptoms and improving quality of life is indicated if the patient has a PS < 2 and no formal contraindications.
- Patients with primary stage IVB or recurrent/persistent, good PS (0 or 1) and measurable disease were randomised to paclitaxel–cisplatin or paclitaxel–topotecan, both with or without bevacizumab.
- In patients progressing following first-line therapy, different cytostatic agents, including vinorelbine, topotecan, gemcitabine or nanoparticle albumin-bound paclitaxel have been evaluated (Table 4).
DOI: 10.1093/annonc/mdx220
View source ↗